Mumbai: Lupin Limited announced that it has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate ...

Loteprednol Etabonate Ophthalmic Suspension, 0.5%, is indicated for the temporary relief of the signs and symptoms of ...

for its Abbreviated New Drug Application for loteprednol etabonate ophthalmic suspension, 0.5%, to market a generic equivalent to the reference listed drug (RLD) Lotemax ophthalmic suspension, 0.5%, ...

The company's product is the generic equivalent of Bausch & Lomb Inc's Lotemax ophthalmic suspension (0.5 per cent), it added. Loteprednol Etabonate ophthalmic suspension, 0.5 per cent, is indicated ...

Two dogs treated at a veterinary hospital in New Jersey last year have tested positive for a rare, drug-resistant strain of bacteria linked to a fatal outbreak blamed on now-recalled eye drops ...

In such a climate, dividend stocks emerge as attractive options, offering potential yields ranging from 5.1% to 6.5%, which could provide a semblance of predictability and income in uncertain times.

Apple’s struggles in China continue, according to new data from research firm Canalys. This data indicates that not only did Apple fall out of first place in China for smartphone shipments in Q1 ...

Loteprednol Etabonate Ophthalmic Suspension, 0.5% (RLD Lotemax), had estimated annual ... Lupin Limited had launched Bromfenac Ophthalmic Solution, 0.075%. Bromfenac Ophthalmic Solution, 0.075% is a ...

2-Year U.S. Treasury Note Continuous Contract $101.340 0.012 0.01% 5-Year U.S. Treasury Note Continuous Contract $104.758 0.016 0.01% 10-Year U.S. Treasury Note Continuous Contract $107.453 0.016 ...

The Discover it® Balance Transfer is no longer available via CNBC Select; offer details mentioned below may no longer apply. Credit card interest rates are typically in the double digits, so ...